250 related articles for article (PubMed ID: 35653929)
1. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
Joshi SR; Rajput R; Chowdhury S; Singh AK; Bantwal G; Das AK; Unnikrishnan AG; Saboo BD; Kesavadev J; Ghosal S; Mohan V
Diabetes Metab Syndr; 2022 Jun; 16(6):102508. PubMed ID: 35653929
[TBL] [Abstract][Full Text] [Related]
2. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Powell J; Piszczatoski C; Taylor JR
Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
[TBL] [Abstract][Full Text] [Related]
3. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
4. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
5. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
6. Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.
Sofogianni A; Tziomalos K
Adv Ther; 2020 Oct; 37(10):4165-4174. PubMed ID: 32886267
[TBL] [Abstract][Full Text] [Related]
7. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
[TBL] [Abstract][Full Text] [Related]
8. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
9. Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
Karásek D
Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
[TBL] [Abstract][Full Text] [Related]
10. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
Mahapatra MK; Karuppasamy M; Sahoo BM
Rev Endocr Metab Disord; 2022 Jun; 23(3):521-539. PubMed ID: 34993760
[TBL] [Abstract][Full Text] [Related]
13. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
14. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
15. Oral semaglutide in type 2 diabetes.
Anderson SL; Beutel TR; Trujillo JM
J Diabetes Complications; 2020 Apr; 34(4):107520. PubMed ID: 31952996
[TBL] [Abstract][Full Text] [Related]
16. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
18. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
Mosenzon O; Miller EM; Warren ML
Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
[TBL] [Abstract][Full Text] [Related]
19. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
